In our previous studies, we assessed the early diagnostic value of autoantibodies against a panel of six TAAs (BMI-1, HSP70, MMP-7, NY-ESO-1, p53 and PRDX6) in esophagogastric junction adenocarcinoma and esophageal squamous cell carcinoma, and the results were validated in independent cohorts 16, 17. This evidence concerns the gene PRDX6 and gastroesophageal junction adenocarcinoma.